Dennis Chang, a Principal at Clarion, joined the firm after PhD and postdoctoral training in neuroscience and molecular genetics. During more than 9 years at Clarion, across ~100 projects, he has blended his strong scientific expertise with commercial strategy to create insight and value for clients in oncology and other specialty markets where innovation is critical to success. Dennis led the development of Clarion’s SPARC (Strategic Pathway Research in Cancer) offering as an opportunity assessment for early-stage pipeline products in oncology, has been deeply involved in market analysis and commercialization strategies for later-stage new products, and led Clarion’s work in support of the CoNNCT (Collaborative Novel-Novel Combination Therapies) initiative, which aims to establish a paradigm for faster, earlier, and broader development of combination regimens for cancer patients.
Wednesday 5/17 @ 4:30 PM RSVP Refreshments will be provided.
Location: Koch Institute at MIT 500 Main Street (Building 76) Room 156 (Auditorium) Cambridge, MA 02139